Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: A double-blind placebo-controlled trial

Journal of Rheumatology

Volumn 35, Issue 5, 2008, Pages 797-803

  Abdou, Nabih I ^a,e   Rider, Virginia ^b   Greenwell, Cindy ^a   Li, Xiaolan ^b,c   Kimler, Bruce F ^d  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b PITTSBURG STATE UNIVERSITY   (United States)

^c KUNMING MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^e ST LUKE S HOSPITAL   (United States)

Author keywords

Bone density T cell activation markers; Calcineurin; CD154; Fulvestrant; Selective estrogen receptor downregulator; Systemic lupus erythematosus; Systemic lupus erythematosus disease activity index

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BIOLOGICAL MARKER; CALCINEURIN; CALCIUM; CD40 LIGAND; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; CREATININE; DOUBLE STRANDED DNA ANTIBODY; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; HEMOGLOBIN; HYDROXYCHLOROQUINE; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; VITAMIN D;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE DENSITY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ESTRADIOL BLOOD LEVEL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MEDICAL RECORD; MENSTRUAL CYCLE; POLYMERASE CHAIN REACTION; PREMENOPAUSE; PRIORITY JOURNAL; SCORING SYSTEM; SEROLOGY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; URINALYSIS;

ADULT; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; BONE DENSITY; CALCINEURIN; CD40 LIGAND; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DOWN-REGULATION; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; QUALITY OF LIFE; RECEPTORS, ESTROGEN; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES;

EID: 44349177616     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hochberg MC. Epidemiology of systemic lupus erythematosus. In: Lahita RG, editor. Systemic lupus erythematosus. New York: Churchill Livingston; 1992:107-17.
2. Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum 1979;22:1195-8.
3. Rider V, Foster RT, Evans M, Suenaga R, Abdou NI. Gender differences in autoimmune diseases: estrogen increases calcineurin expression in systemic lupus erythematosus. Clin Immunol Immunopathol 1998;89:171-80.
4. Rider V, Li X, Peterson G, Dawson J, Kimler BF, Abdou NI. Differential expression of estrogen receptors in women with systemic lupus erythematosus. J Rheumatol 2006;33:1093-101.
5. Roubinian J, Talal N, Süteri PK, Sadakian JA. Sex hormone modulation of autoimmunity in NZB/NZW mice. Arthritis Rheum 1979;22:1162-9.
6. Grimaldi CM. Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells. Curr Opin Rheumatol 2006;18:456-61.
7. Rider V, Jones SR, Evans M, Abdou NI. Molecular mechanisms involved in the estrogen-dependent regulation of calcineurin in systemic lupus erythematosus. Clin Immunol 2000;95:124-34.
8. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
9. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
10. Long X, Nephew KP. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-a. J Biol Chem 2006;281:9607-15.
11. Chan YH. Biostatistics 301A. Repeated measurement analysis (mix models). Singapore Med J 2004;45:456-61.
12. Lethi HD, Wechsler B, Piette JC. Effect of pregnancy, menopause and hormone substitution therapy on disseminated systemic lupus erythematosus. Presse Med 2000;29:55-60.
13. Mok CC, Lau CS, Ho CT, Wong RW. Do flares of systemic lupus erythematosus decline after menopause? Scand J Rheumatol 1999;28:357-62.
14. Sanchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA. Postmenopausal estrogen therapy and the risk of developing systemic lupus erythematosus. Ann Intern Med 1995;122:430-3.
15. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Med 2005;142:953-62.
16. Rider V, Abdou NI. Gender difference in autoimmunity: Molecular basis for estrogen effects in systemic lupus erythematosus. Int Immunopharmacol 2001;1:1009-24.
17. Ariazi EA, Wambi JSL, Gill SD, et al. Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant. Steroid Biochem Molecul Biol 2006;102:128-38.
18. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progesterone in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
19. Apelgren LD, Bailey DL, Fouts RL, et al. The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL lpr/lpr mice. Cell Immunol 1996;173:55-63.
20. Peeva E, Venkatesh J, Diamond B. Tamoxifen blocks estrogen-induced B cell maturation but not survival. J Immunol 2005;175:1415-23.
21. Liu HB, Loo KK, Palaszynski K, Ashouri J, Lubahn DB, Voskuhl RR. Estrogen receptor alpha mediates estrogen immune protection in autoimmune disease. J Immunol 2003;171:6936-40.
22. Lenton EA, Lawrence GF, Coleman RA, Cooke ID. Individual variation in gonadotrophin and steroid concentrations and the lengths of the follicular and luteal phases in women with regular menstrual cycles. Clin Reprod Fertil 1983;2:143-50.
23. Rider V, Jones S, Evans M, Bassiri H, Afsar Z, Abdou NI. Estrogen increases CD40 ligand expression in T cells from women with systemic lupus erythematosus. J Rheumatol 2001;28:2644-9.